Screening relatives of people with type 1 diabetes for early islet autoantibodies
Screens relatives of type 1 diabetes patients for antibodies that signal early disease.
Plain-language title generated from the registry record
Registry title: A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients
Key facts
- Where
- Petah Tikva, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 45 years old?
Source: NCT06665815, who can take part
Where in Israel
- Schneider Children Medical Center of IsraelPetah Tikva, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rabin Medical Center
- Trial code
- NCT06665815
- Record updated
- 20 May 2025
- Original description
A national Screening program for the presence of Islet Autoantibodies (IA) in relatives of people with type 1 diabetes (PWT1D) aiming at identifying people with pre-clinical (stage 1 \& 2) T1D and DKA prevention on the clinical presentation of T1D. All participants will be screened at study entry for the presence of 4 islet autoantibodies: glutamic acid decarboxylase antibody (GADA), insulinoma-associated-2 antibody (IA-2A), insulin antibodies (IAA) and Zinc transporter-8 antibodies (ZnT8A). The ADAP assay will be used to detect IA.Read full original descriptionShow less
A National Screening Program for Islet Autoantibodies Among First-degree Relatives of T1D Patients
A national Screening program for the presence of Islet Autoantibodies (IA) in relatives of people with type 1 diabetes (PWT1D) aiming at identifying people with pre-clinical (stage 1 \& 2) T1D and DKA prevention on the clinical presentation of T1D. All participants will be screened at study entry for the presence of 4 islet autoantibodies: glutamic acid decarboxylase antibody (GADA), insulinoma-associated-2 antibody (IA-2A), insulin antibodies (IAA) and Zinc transporter-8 antibodies (ZnT8A). The ADAP assay will be used to detect IA.
A confirmation blood sample for positive participants with two or more IA will be taken. The confirmation analysis will be done by the ADAP assay, conventional ELISA, and RIA.
Participants identified as part of the study with pre-symptomatic type 1 diabetes (T1D) (stages 1 and 2) will be referred to complete an educational program emphasizing DKA prevention as part of routine medical care .During the study, cases of stage 2 and stage 3 diabetes and DKA events in participants who are positive for IA will be documented.
Inclusion: Age 2-45 years; First-degree relatives of Type 1 Diabetes probands; Signing an informed consent.
Exclusion: Have a previous history of being treated with insulin or oral diabetes medications; Known diabetes of any kind (type 1, type 2, MODY); Currently, using systemic immunosuppressive agents (topical and inhaled agents are acceptable).